Mental Health and Quality of Life among Patients with Cancer during the SARS-CoV-2 Pandemic: Results from the Longitudinal ONCOVID Survey Study.

Emiel A De Jaeghere,Sylvie Rottey,Lore Lapeire,Celine Jacobs,Ingeborg Hilderson,Hannelore G Denys,Paulien West,Aglaja De Pauw,Katrien Vandecasteele,Eline Naert,Vibeke Kruse,Michael Saerens,Roos Colman,Heini Kanervo,Nele Vandemaele,Gilbert Lemmens,Wim Schrauwen,Nora Sundahl

doi:10.3390/cancers14041093

Emiel A De Jaeghere, Sylvie Rottey + Show 16 more

Open Access

https://doi.org/10.3390/cancers14041093

Copy DOI

Abstract

Simple SummaryAlthough the SARS-CoV-2 pandemic is likely to have created or aggravated mental health symptoms in cancer patients, high-quality longitudinal data on this topic are scarce. The aim of our prospective survey study was to assess cancer patient-reported mental health and quality of life (QOL) at four time points during the first two waves of the pandemic. We found that an important proportion of the 355 participants reported symptoms of COVID-19 peritraumatic distress (34.2% to 39.6%), depression (27.6% to 33.5%), anxiety (24.9% to 32.7%), and stress (11.4% to 15.7%) at any time point during the study period. However, we did not find clinically meaningful mental health and QOL changes during the study period. Additionally, we found no factors associated with better or worse mental health or QOL. In conclusion, the cancer patients who participated in this study showed considerable resilience against mental health and QOL deterioration during the pandemic.Purpose: This longitudinal survey study aimed to investigate the self-reported outcome measures of COVID-19 peritraumatic distress, depression, anxiety, stress, quality of life (QOL), and their associated factors in a cohort of cancer patients treated at a tertiary care hospital during the SARS-CoV-2 pandemic. Methods: Surveys were administered at four time points between 1 April 2020 and 18 September 2020. The surveys included the CPDI, DASS-21, and WHOQOL-BREF questionnaires. Results: Survey response rates were high (61.0% to 79.1%). Among the 355 participants, 71.3% were female, and the median age was 62.2 years (IQR, 53.9 to 69.1). The majority (78.6%) were treated with palliative intention. An important proportion of the participants reported symptoms of COVID-19 peritraumatic distress (34.2% to 39.6%), depression (27.6% to 33.5%), anxiety (24.9% to 32.7%), and stress (11.4% to 15.7%) at any time point during the study period. We did not find clinically meaningful mental health and QOL differences during the study period, with remarkably little change in between the pandemic’s first and second wave. We found no consistent correlates of mental health or QOL scores, including cancer type, therapy intention, and sociodemographic information. Conclusion: This cohort of cancer patients showed considerable resilience against mental health and QOL deterioration during the SARS-CoV-2 pandemic.

Highlights

In late 2019, the first pneumonia cases of unknown origin were identified in Wuhan (Hubei, China) [1]
Bonferroni-corrected post hoc thresholds were applied after obtaining significant results: i significant differences in pairwise comparisons: none; ii significant differences in pairwise comparisons: none; iii significant differences in pairwise comparisons: none; iv significant differences in pairwise comparisons: none; v significant differences in pairwise comparisons: none. vi significant differences in pairwise comparisons: none. This longitudinal survey study examined the course of multiple mental health symptoms and quality of life (QOL) during the SARS-CoV-2 pandemic in a cohort of patients with cancer receiving systemic anticancer therapy
Many participants experienced mental health symptoms, it should be noted that our results provide more grounds for optimism than those reported in other studies

Summary

Introduction

In late 2019, the first pneumonia cases of unknown origin were identified in Wuhan (Hubei, China) [1]. The pathogen was identified as a novel enveloped ribonucleic acid human β-coronavirus that was named severe acute respiratory syndrome coronavirus 2. (COVID-19), ranges from self-limiting upper respiratory tract illness to life-threatening pneumonia, multiorgan failure, and death [2]. Given the rapid and global spread of SARSCoV-2, the World Health Organization (WHO) officially declared it a pandemic in March. The SARS-CoV-2 pandemic and its myriad containment measures have affected all aspects of society, including cancer care across the entire disease trajectory [4,5]. The prevalence of mental health symptoms (such as depressive symptoms, anxiety, and stress) in cancer patients is known to be significant [6]; the SARS-CoV-2 pandemic is likely to have induced or exacerbated them in this vulnerable population

Methods

Results

Discussion

Conclusion